Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07054060

Endarterectomy Versus Stenting in Patients With Symptomatic Severe Carotid Stenosis - 2

Carotid stenosis caused by atherosclerosis is a significant risk factor for ischemic stroke, accounting for up to 15% of all strokes and transient ischemic attacks. Randomized clinical trials (RCTs) have demonstrated the benefits of carotid endarterectomy (CEA) in reducing stroke risk in patients with severe symptomatic carotid stenosis. Carotid artery stenting (CAS) has been developed as an alternative to CEA, offering several potential advantages, such as avoiding local surgical complications. However, unlike CEA, CAS has not been compared to medical therapy in RCTs for symptomatic carotid stenosis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre hospitalier Sainte-Anne

Paris, 75014, France

Location status: Recruiting

Location contact

David Calvet

CONTACT

[email protected]

About this study

CEA vs CAS Comparison:

Early RCTs conducted in the 2000s showed that CAS was associated with a higher risk of procedural stroke or death compared to CEA (8.9% vs 5.8%; RR 1.53, 95% CI 1.20-1.96, p=0.0006). However, CAS was found to be as effective as CEA in preventing recurrent ipsilateral strokes up to 10 years after treatment. Interestingly, an ancillary study of the ICSS trial showed that significantly more patients in the CAS group (50%) than in the CEA group (17%) had new ischemic lesions on diffusion-weighted MRI (DWI), suggesting that DWI might serve as a surrogate outcome measure for future carotid intervention trials.

Data Analysis and Recent Advances:

Individual pooled data analysis of RCTs indicated that CAS could be as safe and effective as CEA in patients under 70 years old. Recent advances in CAS technology, stenting techniques, antiplatelet therapy, and pre-treatment imaging have improved the periprocedural safety of CAS. Due to its ability to treat patients soon after a stroke, CAS has become increasingly used in routine clinical practice.

Study Objectives:

The question remains whether CAS is as safe as CEA in patients with recent symptomatic severe carotid stenosis. The study's objectives are:

Primary Objective:

To assess whether carotid stenting is non-inferior to carotid endarterectomy in preventing new ischemic lesions on DWI MRI, confirmed by a core lab.

  • To assess the difference between groups regarding post-intervention MRI characteristics in terms of ischemic lesion number and size, vessel occlusion and hemorrhagic transformation
  • To assess differences between groups with regard to the procedural risks and efficacy (within 30 days after procedure) of
  • any stroke or death
  • any stroke,
  • disabling or fatal stroke
  • death
  • transient ischemic attack
  • myocardial infarction
  • local complication
  • cranial nerve palsy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient age 18 years or over
  • Hemispheric or retinal transient ischemic attack or a non-disabling stroke (or retinal infarct) within 15 days before enrolment
  • Stenosis of 50% to 99% in the symptomatic carotid artery (NASCET method) for whom revascularisation is decided according to guidelines

Exclusion criteria

  • Patients unwilling or unable to participate in follow-up for whatever reason
  • Preexisting disability (Modified Rankin Score ≥ 3)
  • Nonatherosclerotic carotid disease
  • Severe tandem lesions
  • Previous revascularization of the symptomatic carotid stenosis
  • History of bleeding disorder
  • Unstable angina
  • Contraindication to dual antiplatelet therapy
  • Contraindication to MRI
  • Life expectancy of less than 2 years
  • Percutaneaous or surgical intervention within 30 days before or after the study procedure
  • Stenotic lesion on arterial workup appeared as not a factor in the selection

Treatment and study plan

carotid endarterectomy

Procedure

Carotid endarterectomy is a surgical procedure used to reduce the risk of stroke due to carotid artery stenosis. During an endarterectomy, the surgeon opens the artery and removes the plaque.

Carotid Artery Stenting

Procedure

Carotid artery stenting is an endovascular procedure in which a stent is deployed in the lumen of the carotid artery to treat narrowing of the carotid artery and reduce the risk of stroke.

Primary outcomes

  1. DWI Lesion Detection Rate

    Time frame: From 3 days before procedure to 7 days after procedure

    Imaging endpoint : Proportion of patients having at least one new lesion on post-treatment Diffusion-Weigthed Imaging (DWI) MRI compared to pre-treatment DWI MRI and confirmed by a core lab.

    The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.

Secondary outcomes

  1. Profile of lesions

    Time frame: From 3 days before procedure to 7 days after procedure

    Imaging endpoint : Number and size of new lesions on post-treatment MRI. The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.

  2. Vessel Occlusion Profile

    Time frame: From 3 days before procedure to 7 days after procedure

    Imaging endpoint : Proportion of patients having a new intracranial vessel occlusion on post-treatment MRI.

    The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.

  3. Hemorrhage

    Time frame: From 3 days before procedure to 7 days after procedure

    Imaging endpoint : Hemorrhagic transformation on post-treatment MRI. The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.

  4. Stroke/Mortality

    Time frame: From randomization to 30 days after procedure

    Clinical endpoint : proportion of patients having any stroke or death during periprocedural period.

  5. Stroke Incidence Rate

    Time frame: From randomization to 30 days after procedure

    Clinical endpoint : Proportion of patients having any stroke during periprocedural period.

  6. Severe Stroke Incidence

    Time frame: From randomization to 30 days after procedure

    Clinical endpoint : Proportion of patients having any disabling or fatal stroke during periprocedural period.

  7. Mortality

    Time frame: From randomization to 30 days after procedure

    Clinical endpoint : Proportion of patients who died during periprocedural period.

  8. TIA Incidence

    Time frame: From randomization to 30 days after procedure

    Clinical endpoint : Proportion of patients having a Transient ischemic attack during periprocedural period.

  9. MI Occurrence

    Time frame: From randomization to 30 days after procedure

    Clinical endpoint : Proportion of patients having myocardial infarction during periprocedural period.

  10. Local complication

    Time frame: From randomization to 30 days after procedure

    Clinical endpoint : cervical or groin or radial hematoma, infection, arteriovenous fistula at puncture site, lower-limb arterial occlusion during periprocedural period.

  11. Cranial Nerve Injury Events

    Time frame: From randomization to 30 days after procedure

    Clinical endpoint : Proportion of patients having cranial nerve injury during periprocedural period.

  12. Hospitalization Duration

    Time frame: From the date of the carotid artery stenting (CAS) or endarterectomy (CEA) procedure until the date of hospital discharge, assessed up to 30 days

    Healthcare endpoint : number of days the patient stayed in the hospital stay

  13. Procedure Delay

    Time frame: From the date of patient randomization until the date of carotid artery stenting (CAS) or endarterectomy (CEA) procedure, assessed up to 15 days

    Operational endpoint: number of days between the date at which the patient is randomized and the date at which the carotid artery stenting (CAS) or endarterectomy) is proceeded

  14. Ischemic Events

    Time frame: From 3 days before procedure to 7 days after procedure.

    Clinical endpoint: Incidence of ischemic events among patients with confirmed new lesions on post-procedure DWI MRI (as verified by core lab assessment). The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.

  15. Hemorrhage

    Time frame: From 3 days before procedure to 7 days after procedure.

    Imaging endpoint : Hemorrhagic transformation on post-treatment MRI. The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.

Study contacts

Contact information is provided by the study sponsor or research team.

DRCI DRCI

CONTACT

[email protected]

David Calvet, Professor

CONTACT

[email protected]

+33145658634

Sponsors and collaborators

Lead sponsor

Centre Hospitalier St Anne

Other

Collaborators

  • Direction Générale de l'Offre de Soins

Registry information

Acronym: EVA3S-2

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jul 8, 2025
Registry last updated
Jul 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.